Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?

NCT ID NCT07730151

Not yet recruiting Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether adding darolutamide to standard chemotherapy and hormone therapy before prostate removal can improve long-term outcomes for men with locally advanced prostate cancer. Participants receive either the triple combination or the standard two-drug regimen for 16 weeks before surgery, then are followed for three years. The study aims to see if the extra drug delays cancer recurrence and reduces the chance of the cancer becoming resistant to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darolutamide, docetaxel, and ADT (androgen deprivation therapy)
What this could lead to: If successful, this combination could become a standard pre-surgery treatment to reduce cancer recurrence in locally advanced prostate cancer.
What could go wrong: This is a Phase 2 trial with a moderate sample size, so results may not be definitive. Adding darolutamide could increase side effects like fatigue, hot flashes, or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE PROSTATE CANCER PROSTATE CANCER PATIENTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.